Mumbai, June 10 -- The stock has rallied 20.25% over the last five trading sessions. It has gained 28.03% in one month, 41.16% in three months and 32.28% so far in 2026.

Caplin Point Laboratories is a fully integrated pharmaceutical company with a strong presence in Latin America.

The company reported a 19.32% increase in consolidated net profit to Rs 170.11 crore in Q4 FY26, compared with Rs 142.57 crore in Q4 FY25. Revenue from operations rose 19.45% to Rs 600.16 crore from Rs 502.43 crore a year earlier.

For FY26, emerging markets comprising Latin America and Africa contributed 79% of revenue, while the US market accounted for the remaining 21%.

Last month, Caplin Steriles, a subsidiary of the company, received final approval from ...